Literature for alogliptin (S09.003 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2016
1. Arulmozhiraja,S., Matsuo,N., Ishitsubo,E., Okazaki,S., Shimano,H. and Tokiwa,H.
   Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs - an ab initio fragment molecular orbital study
   PLoS ONE11, e0166275-e0166275. PubMed  Europe PubMed DOI  I
2015
2. Gilibili,R.R., Bhamidipati,R.K., Mullangi,R. and Srinivas,N.R.
   Retrospective and prospective human intravenous and oral pharmacokinetic projection of dipeptidyl peptidase-IV inhibitors using simple allometric principles - case studies of ABT-279, ABT-341, alogliptin, carmegliptin, sitagliptin and vildagliptin
   J Pharm Pharm Sci18, 434-448. PubMed  Europe PubMed  I
2013
3. Nabeno,M., Akahoshi,F., Kishida,H., Miyaguchi,I., Tanaka,Y., Ishii,S. and Kadowaki,T.
   A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
   Biochem Biophys Res Commun434, 191-196. PubMed  Europe PubMed DOI  I
4. Xie,H., Zeng,L., Zeng,S., Lu,X., Zhao,X., Zhang,G., Tu,Z., Xu,H., Yang,L., Zhang,X., Wang,S. and Hu,W.
   Highly potent dipeptidyl peptidase IV inhibitors derived from alogliptin through pharmacophore hybridization and lead optimization
   Eur J Med Chem68, 312-320. PubMed  Europe PubMed DOI  I
2012
5. Gibbs,J.P., Fredrickson,J., Barbee,T., Correa,I., Smith,B., Lin,S.L. and Gibbs,M.A.
   Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results
   J Clin Pharmacol52, 1494-1505. PubMed  Europe PubMed DOI  I
6. Monami,M., Lamanna,C., Desideri,C.M. and Mannucci,E.
   DPP-4 Inhibitors and lipids: systematic review and meta-analysis
   Adv Ther29, 14-25. PubMed  Europe PubMed DOI  I
2011
7. Shah,Z., Kampfrath,T., Deiuliis,J.A., Zhong,J., Pineda,C., Ying,Z., Xu,X., Lu,B., Moffatt-Bruce,S., Durairaj,R., Sun,Q., Mihai,G., Maiseyeu,A. and Rajagopalan,S.
   Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis
   Circulation124, 2338-2349. PubMed  Europe PubMed DOI  I
2009
8. Asakawa,T., Moritoh,Y., Kataoka,O., Suzuki,N., Takeuchi,K. and Odaka,H.
   A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure
   Life Sci85, 122-126. PubMed  Europe PubMed DOI  I
2008
9. Moritoh,Y., Takeuchi,K., Asakawa,T., Kataoka,O. and Odaka,H.
   Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
   Eur J Pharmacol588, 325-332. PubMed  Europe PubMed DOI  I
10. Wang,Y., Serradell,N., Rosa,E. and Bolos,J.
    Alogliptin benzoate. Dipeptidyl-peptidase IV (DPP IV) inhibitor treatment of type 2 diabetes
    Drugs Future33, 7-12. DOI  I